Switch theme
Sign up to access all valuation multiples
Aiforia Technologies PLC equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services plan to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more.
2018
75
LTM Revenue $4.1M
LTM EBITDA -$8.7M
$104M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aiforia has a last 12-month revenue (LTM) of $4.1M and a last 12-month EBITDA of -$8.7M.
In the most recent fiscal year, Aiforia achieved revenue of $3.2M and an EBITDA of -$8.4M.
Aiforia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aiforia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | XXX | $3.2M | XXX | XXX | XXX |
| Gross Profit | $4.1M | XXX | $2.5M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | -$8.7M | XXX | -$8.4M | XXX | XXX | XXX |
| EBITDA Margin | -213% | XXX | -263% | XXX | XXX | XXX |
| EBIT | -$13.6M | XXX | -$13.7M | XXX | XXX | XXX |
| EBIT Margin | -331% | XXX | -428% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$13.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -419% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aiforia's stock price is EUR 3 (or $4).
Aiforia has current market cap of EUR 97.9M (or $110M), and EV of EUR 93.0M (or $104M).
See Aiforia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $110M | XXX | XXX | XXX | XXX | $-0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aiforia has market cap of $110M and EV of $104M.
Aiforia's trades at 32.6x EV/Revenue multiple, and -12.4x EV/EBITDA.
Equity research analysts estimate Aiforia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aiforia's P/E ratio is not available.
See valuation multiples for Aiforia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV/Revenue | 25.5x | XXX | 32.6x | XXX | XXX | XXX |
| EV/EBITDA | -12.0x | XXX | -12.4x | XXX | XXX | XXX |
| EV/EBIT | -7.7x | XXX | -7.6x | XXX | XXX | XXX |
| EV/Gross Profit | 25.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -8.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAiforia's last 12 month revenue growth is 62%
Aiforia's revenue per employee in the last FY averaged $43K, while opex per employee averaged $0.2M for the same period.
Aiforia's rule of 40 is -337% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aiforia's rule of X is -58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aiforia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 62% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Margin | -213% | XXX | -263% | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -337% | XXX | -201% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $43K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 507% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aiforia acquired XXX companies to date.
Last acquisition by Aiforia was XXXXXXXX, XXXXX XXXXX XXXXXX . Aiforia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aiforia founded? | Aiforia was founded in 2018. |
| Where is Aiforia headquartered? | Aiforia is headquartered in Finland. |
| How many employees does Aiforia have? | As of today, Aiforia has 75 employees. |
| Is Aiforia publicy listed? | Yes, Aiforia is a public company listed on HEL. |
| What is the stock symbol of Aiforia? | Aiforia trades under AIFORIA ticker. |
| When did Aiforia go public? | Aiforia went public in 2021. |
| Who are competitors of Aiforia? | Similar companies to Aiforia include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Aiforia? | Aiforia's current market cap is $110M |
| What is the current revenue of Aiforia? | Aiforia's last 12 months revenue is $4.1M. |
| What is the current revenue growth of Aiforia? | Aiforia revenue growth (NTM/LTM) is 62%. |
| What is the current EV/Revenue multiple of Aiforia? | Current revenue multiple of Aiforia is 25.5x. |
| Is Aiforia profitable? | Yes, Aiforia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aiforia? | Aiforia's last 12 months EBITDA is -$8.7M. |
| What is Aiforia's EBITDA margin? | Aiforia's last 12 months EBITDA margin is -213%. |
| What is the current EV/EBITDA multiple of Aiforia? | Current EBITDA multiple of Aiforia is -12.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
